UK markets close in 1 hour 14 minutes

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.0250-0.0450 (-1.47%)
As of 10:14AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 263.59M
Enterprise value 108.21M
Trailing P/E 11.63
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.27
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.49

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3-52.70%
S&P500 52-week change 3-15.36%
52-week high 38.1400
52-week low 32.0600
50-day moving average 33.0941
200-day moving average 33.7078

Share statistics

Avg vol (3-month) 358.24k
Avg vol (10-day) 3124.3k
Shares outstanding 583.41M
Implied shares outstanding 6N/A
Float 832.74M
% held by insiders 147.74%
% held by institutions 118.21%
Shares short (14 Sept 2022) 4460.3k
Short ratio (14 Sept 2022) 410.23
Short % of float (14 Sept 2022) 41.17%
Short % of shares outstanding (14 Sept 2022) 40.55%
Shares short (prior month 14 Aug 2022) 4461.31k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CHF.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-23.88%
Return on equity (ttm)-38.60%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-62.28M
EBITDA -79.88M
Net income avi to common (ttm)-75.68M
Diluted EPS (ttm)-0.9990
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)154.15M
Total cash per share (mrq)1.83
Total debt (mrq)2.63M
Total debt/equity (mrq)1.29
Current ratio (mrq)13.28
Book value per share (mrq)2.40

Cash flow statement

Operating cash flow (ttm)-74.95M
Levered free cash flow (ttm)-47.52M